PMID- 33810248
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240331
IS  - 2072-6694 (Print)
IS  - 2072-6694 (Electronic)
IS  - 2072-6694 (Linking)
VI  - 13
IP  - 7
DP  - 2021 Mar 26
TI  - The Flt3L/Flt3 Axis in Dendritic Cell Biology and Cancer Immunotherapy.
LID - 10.3390/cancers13071525 [doi]
LID - 1525
AB  - Dendritic cells (DCs) prime anti-tumor T cell responses in tumor-draining lymph 
      nodes and can restimulate T effector responses in the tumor site. Thus, in 
      addition to unleashing T cell effector activity, current immunotherapies should 
      be directed to boost DC function. Herein, we review the potential function of 
      Flt3L as a tool for cancer immunotherapy. Flt3L is a growth factor that acts in 
      Flt3-expressing multipotent progenitors and common lymphoid progenitors. Despite 
      the broad expression of Flt3 in the hematopoietic progenitors, the main effect of 
      the Flt3/Flt3L axis, revealed by the characterization of mice deficient in these 
      genes, is the generation of conventional DCs (cDCs) and plasmacytoid DCs (pDCs). 
      However, Flt3 signaling through PI3K and mTOR may also affect the function of 
      mature DCs. We recapitulate the use of Flt3L in preclinical studies either as a 
      single agent or in combination with other cancer therapies. We also analyze the 
      use of Flt3L in clinical trials. The strong correlation between type 1 cDC (cDC1) 
      infiltration of human cancers with overall survival in many cancer types suggests 
      the potential use of Flt3L to boost expansion of this DC subset. However, this 
      may need the combination of Flt3L with other immunomodulatory agents to boost 
      cancer immunotherapy.
FAU - Cueto, Francisco J
AU  - Cueto FJ
AUID- ORCID: 0000-0002-7457-9583
AD  - Centro Nacional de Investigaciones Cardiovasculares (CNIC), 28029 Madrid, Spain.
FAU - Sancho, David
AU  - Sancho D
AD  - Centro Nacional de Investigaciones Cardiovasculares (CNIC), 28029 Madrid, Spain.
LA  - eng
GR  - ERC-2016-Consolidator Grant 725091/ERC_/European Research Council/International
GR  - PID2019-108157RB/Agencia Estatal de Investigacion/
GR  - B2017/BMD-3733 Immunothercan-CM/Comunidad de Madrid/
GR  - 201723/Fundacio la Marato de TV3/
GR  - Fondo Solidario Juntos/Banco Santander/
PT  - Journal Article
PT  - Review
DEP - 20210326
PL  - Switzerland
TA  - Cancers (Basel)
JT  - Cancers
JID - 101526829
PMC - PMC8037622
OTO - NOTNLM
OT  - Flt3
OT  - Flt3L
OT  - cancer immunotherapy
OT  - dendritic cells
COIS- The authors declare no conflict of interest.
EDAT- 2021/04/04 06:00
MHDA- 2021/04/04 06:01
PMCR- 2021/03/26
CRDT- 2021/04/03 01:35
PHST- 2021/02/28 00:00 [received]
PHST- 2021/03/21 00:00 [revised]
PHST- 2021/03/23 00:00 [accepted]
PHST- 2021/04/03 01:35 [entrez]
PHST- 2021/04/04 06:00 [pubmed]
PHST- 2021/04/04 06:01 [medline]
PHST- 2021/03/26 00:00 [pmc-release]
AID - cancers13071525 [pii]
AID - cancers-13-01525 [pii]
AID - 10.3390/cancers13071525 [doi]
PST - epublish
SO  - Cancers (Basel). 2021 Mar 26;13(7):1525. doi: 10.3390/cancers13071525.